Drugs / Iza-bren
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07382726 | Jul 2026 → Dec 2027 expected | non-small cell lung carcinoma | M.D. Anderson Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT07100080 | Nov 2025 → Dec 2028 expected | non-small cell lung carcinoma | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07106762 | Sep 2025 → Jan 2029 expected | urothelial carcinoma | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06926868 | Sep 2025 → Mar 2028 expected | breast neoplasm | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07680790 | Sep 2026 → Dec 2031 expected | non-small cell lung carcinoma | Bristol-Myers Squibb | Not yet recruiting | No outcome recorded |
Press releases naming this drug 19 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | iza-bren | “This research is being done to test a combination of two drugs, Izalontamab Brengitecan (iza-bren) and Adagrasib, in patients with advanced KRAS G12C-mutant NSCLC that hasn't...” NCT07382726 ↗ |
| Known as | Izalontamab Brengitecan | “This research is being done to test a combination of two drugs, Izalontamab Brengitecan (iza-bren) and Adagrasib, in patients with advanced KRAS G12C-mutant NSCLC that hasn't...” NCT07382726 ↗ |
| Route | Intravenous | “Given by IV” NCT07382726 ↗ |
| Target | EGFR | “a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload” NCT06926868 ↗ |